首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   488篇
  免费   179篇
  国内免费   6篇
耳鼻咽喉   10篇
儿科学   11篇
妇产科学   6篇
基础医学   1篇
口腔科学   66篇
临床医学   139篇
内科学   151篇
皮肤病学   9篇
神经病学   63篇
特种医学   25篇
外科学   103篇
预防医学   31篇
眼科学   2篇
药学   4篇
肿瘤学   52篇
  2024年   4篇
  2023年   33篇
  2022年   14篇
  2021年   24篇
  2020年   31篇
  2019年   28篇
  2018年   49篇
  2017年   48篇
  2016年   44篇
  2015年   47篇
  2014年   37篇
  2013年   39篇
  2012年   12篇
  2011年   17篇
  2010年   38篇
  2009年   36篇
  2008年   22篇
  2007年   10篇
  2006年   15篇
  2005年   7篇
  2004年   1篇
  2003年   2篇
  2002年   7篇
  2001年   9篇
  2000年   4篇
  1999年   7篇
  1998年   12篇
  1997年   10篇
  1996年   14篇
  1995年   10篇
  1994年   10篇
  1993年   8篇
  1992年   5篇
  1991年   2篇
  1990年   5篇
  1989年   1篇
  1988年   4篇
  1987年   1篇
  1985年   1篇
  1982年   2篇
  1981年   2篇
  1980年   1篇
排序方式: 共有673条查询结果,搜索用时 0 毫秒
11.
In order to assess the applicability of a bedside coagulometer for measurement of b-APTT, serial blood samples were obtained from 20 patients receiving intravenous heparin treatment following PTCA, and from 5 healthy volunteers. B-APTT was analysed bedside on the Hemochron® coagulometer; p-APTT and p-heparin, measured asfactor anti-Xa activity, were analysed ex-vivo in the laboratory. B-APTT values, determined by the Hemochron coagulometer, were closely correlated to p-heparin (r=0.83, p<0.001, SD=52 seconds (sec), n=89), and duplicate determinations of b-APTT on the Hemochron coagulometer showed an acceptable repeatability. However, an APTT ratio of 1.5–2.5 was not related to a therapeutic p-heparin level, neither as measured by the Hemochron device nor in the laboratory. Abstract. Background: When administering intravenous heparin during angioplasty procedures, a quick and reliable method for safe and effective monitoring of anticoagulation is necessary. Objective: To assess the applicability of a bedside coagulometer, measuring the activated partial thromboplastin time (APTT) in patients receiving intravenous heparin treatment after percutaneous transluminal coronary angioplasty (PTCA). Methods: In patients with stable angina pectoris, receiving intravenous heparin treatment following PTCA, serial blood samples were obtained by venipuncture and from the arterial sheath for analysis of whole blood APTT (b-APTT), and plasma heparin concentration (p-heparin). Additionally, in healthy volunteers blood samples were obtained after a single bolus injection of heparin. B-APTT was analysed bedside on the Hemochron® coagulometer; p-APTT and p-heparin, measured as factor anti-Xa activity, were analysed ex-vivo in the laboratory using conventional analytical methods. Results: In 20 patients a total of 94 venous and 69 arterial blood samples were analysed, and in five healthy volunteers analyses were performed in 20 venous blood samples. B-APTT values, determined by the Hemochron coagulometer, were closely correlated to p-heparin (r=0.83, p<0.001, SD=52 seconds (sec), n=89). An APTT ratio of 1.5–2.5 was not related to a therapeutic p-heparin level, however, neither when using APTT assessed by the Hemochron device nor APTT measured in the laboratory. Duplicate determinations of b-APTT on the Hemochron coagulometer showed an acceptable repeatability; the mean difference between duplicate measurements was 4[emsp4 ] sec (coefficient of variation (c.v.)=6%, p<0.05, n=163). Conclusions: In patients receiving intravenous heparin after PTCA treatment, b-APTT values measured by the Hemochron method showed an acceptable repeatability and were significantly correlated to p-heparin.  相似文献   
12.
13.
14.
15.
16.
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号